Nasdaq · Healthcare

TScan Therapeutics, Inc. (TCRX)

As-reported financials and recent SEC filings for TScan Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$10.3M

Net income

$-129.8M

Net margin

—

Diluted EPS

$-1.00

ROE

-105.4%

P/E (TTM)

—

Market cap

—

Debt / equity

0.3×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$10.3M	$2.8M	$21.0M	$13.5M	$10.1M
Gross profit	—	—	—	—	—
Operating income	$-135.8M	$-134.8M	$-93.5M	$-66.6M	$-48.6M
Net income	$-129.8M	$-127.5M	$-89.2M	$-66.2M	$-48.6M
Diluted EPS	$-1.00	$-1.14	$-1.36	$-0.92	$-0.69

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-22

42026-05-22

8-K2026-05-22

42026-05-22

42026-05-22

42026-05-22

42026-05-22

42026-05-22

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on TCRX

Search TScan Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.